三生国健: 安永华明会计师事务所（特殊普通合伙）对公司2024年度募集资金存放与使用情况鉴证报告

Core Viewpoint - The report provides an independent verification of the fundraising management and usage of Sangfor Technologies (Shanghai) Co., Ltd. for the year 2024, confirming compliance with regulatory requirements and reflecting the actual status of the funds raised [2][3]. Fundraising Overview - The total amount raised through the initial public offering (IPO) was RMB 1,736,483,781.56, with a net amount of RMB 1,634,428,187.64 after deducting underwriting fees and other expenses [5][6]. - The funds were raised through the issuance of 61,621,142 shares at a price of RMB 28.18 per share, approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission [5][6]. Fund Management - The company established a dedicated fund management system, including a special account storage system to ensure the proper management and usage of the raised funds [8][9]. - The company signed tripartite and quadripartite agreements with banks and underwriters to clarify the rights and obligations of all parties involved in the management of the funds [8][9]. Fund Usage - As of December 31, 2024, the remaining balance of the raised funds was RMB 164,789,265.16, after accounting for various expenditures and investments [6][9]. - The funds were primarily allocated to projects related to the company's main business and to supplement working capital [10]. Adjustments to Fund Allocation - The company adjusted the investment amounts for specific projects, increasing the budget for the "New Drug Research and Development Project for Autoimmune and Ocular Diseases" from RMB 25 million to RMB 61 million, while reducing the budget for the "Research and Development Center Construction Project" [11][13]. - The adjustments were made to enhance the feasibility and effectiveness of the projects without significant changes in project viability [12][13].